Tobira Therapeutics Inc. (NASDAQ:TBRA) shares saw strong trading volume on Wednesday . 1,001,460 shares traded hands during mid-day trading, an increase of 68% from the previous session’s volume of 596,746 shares.The stock last traded at $3.95 and had previously closed at $3.95.

Several equities research analysts have issued reports on the company. Zacks Investment Research upgraded Tobira Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a report on Friday, July 29th. Cantor Fitzgerald downgraded Tobira Therapeutics to a “buy” rating and set a $19.00 price target for the company. in a report on Monday, July 25th. HC Wainwright restated a “buy” rating on shares of Tobira Therapeutics in a report on Tuesday, June 28th. Cowen and Company restated a “buy” rating on shares of Tobira Therapeutics in a report on Tuesday, May 10th. Finally, Leerink Swann restated a “buy” rating and issued a $18.00 price target on shares of Tobira Therapeutics in a report on Tuesday, May 10th. Five research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus target price of $16.95.

The stock has a 50-day moving average price of $9.41 and a 200-day moving average price of $8.46. The stock’s market capitalization is $75.07 million.

Tobira Therapeutics (NASDAQ:TBRA) last announced its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by $0.08. The firm earned $1.06 million during the quarter. Analysts anticipate that Tobira Therapeutics Inc. will post ($2.49) EPS for the current year.

In related news, major shareholder A/S Novo sold 66,814 shares of the business’s stock in a transaction dated Thursday, June 30th. The stock was sold at an average price of $13.04, for a total value of $871,254.56. Following the completion of the sale, the insider now directly owns 2,073,022 shares of the company’s stock, valued at approximately $27,032,206.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

An institutional investor recently bought a new position in Tobira Therapeutics stock. Marshall Wace LLP bought a new position in shares of Tobira Therapeutics Inc. (NASDAQ:TBRA) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 107,493 shares of the biopharmaceutical company’s stock, valued at approximately $1,080,000. Marshall Wace LLP owned 0.57% of Tobira Therapeutics as of its most recent SEC filing.

Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.